1. Home
  2. SCYX vs KOSS Comparison

SCYX vs KOSS Comparison

Compare SCYX & KOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • KOSS
  • Stock Information
  • Founded
  • SCYX 1999
  • KOSS 1953
  • Country
  • SCYX United States
  • KOSS United States
  • Employees
  • SCYX N/A
  • KOSS N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • KOSS Consumer Electronics/Appliances
  • Sector
  • SCYX Health Care
  • KOSS Consumer Staples
  • Exchange
  • SCYX Nasdaq
  • KOSS Nasdaq
  • Market Cap
  • SCYX 40.9M
  • KOSS 46.1M
  • IPO Year
  • SCYX 2014
  • KOSS N/A
  • Fundamental
  • Price
  • SCYX $1.03
  • KOSS $5.30
  • Analyst Decision
  • SCYX Buy
  • KOSS
  • Analyst Count
  • SCYX 1
  • KOSS 0
  • Target Price
  • SCYX N/A
  • KOSS N/A
  • AVG Volume (30 Days)
  • SCYX 135.5K
  • KOSS 41.6K
  • Earning Date
  • SCYX 03-12-2025
  • KOSS 05-08-2025
  • Dividend Yield
  • SCYX N/A
  • KOSS N/A
  • EPS Growth
  • SCYX N/A
  • KOSS N/A
  • EPS
  • SCYX N/A
  • KOSS N/A
  • Revenue
  • SCYX $3,746,000.00
  • KOSS $12,289,961.00
  • Revenue This Year
  • SCYX $1,541.00
  • KOSS N/A
  • Revenue Next Year
  • SCYX $111.43
  • KOSS N/A
  • P/E Ratio
  • SCYX N/A
  • KOSS N/A
  • Revenue Growth
  • SCYX N/A
  • KOSS N/A
  • 52 Week Low
  • SCYX $0.82
  • KOSS $2.27
  • 52 Week High
  • SCYX $3.07
  • KOSS $18.73
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 50.55
  • KOSS 52.93
  • Support Level
  • SCYX $1.00
  • KOSS $4.99
  • Resistance Level
  • SCYX $1.06
  • KOSS $5.88
  • Average True Range (ATR)
  • SCYX 0.07
  • KOSS 0.33
  • MACD
  • SCYX 0.02
  • KOSS 0.12
  • Stochastic Oscillator
  • SCYX 63.30
  • KOSS 82.76

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.

Share on Social Networks: